AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash
Big time M&A is back. But for how long?
Over the past 18 months we’ve now seen three major buyouts announced: Takeda/Shire; Bristol-Myers/Celgene and now AbbVie/Allergan. And with this latest deal it’s increasingly clear that the sharp fall from grace suffered by high-profile players which have seen their share prices blasted has created an opening for the growth players in big pharma to up their game — in sharp contrast to the popular bolt-on deals that have been driving the growth strategy at Novartis, Merck, Roche and others.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.